0
Signin
countryflagUS

18889881171

AAPL 169.38 0.213% MSFT 395.01 -3.4347% GOOG 157.28 -2.3712% GOOGL 155.62 -2.2057% AMZN 172.26 -2.452% NVDA 822.64 3.2469% META 437.68 -11.311% TSLA 164.345 1.3662% TSM 136.66 2.7751% LLY 726.29 -0.8072% V 274.6 -0.1527% AVGO 1296.3043 3.1416% JPM 193.3 0.1139% UNH 494.74 1.5268% NVO 125.02 -0.9036% WMT 60.51 1.069% LVMUY 167.4155 -2.4499% XOM 120.83 -0.1817% LVMHF 839.31 -2.3774% MA 461.62 -0.1903%

Hepion Pharmaceuticals Inc

Healthcare US HEPA

1.3453USD
0.03(1.92%)

Last update at 2024-04-25T16:54:00Z

Day Range

1.271.35
LowHigh

52 Week Range

2.5523.85
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -45.08390M -32.72217M -20.32335M -7.94602M -9.98530M
Minority interest - - - - -
Net income -42.20005M -32.73103M -20.35394M -6.71870M -9.44929M
Selling general administrative 10.35M 10.01M 8.15M 4.59M 7.00M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.08M 0.09M 0.03M 0.03M 0.02M
Ebit -45.48873M -30.40331M -20.14607M -7.77008M -14.59416M
Ebitda -43.54034M -30.31724M -20.11156M -7.92300M -19.63234M
Depreciation and amortization 1.95M 0.09M 0.03M -0.15291M -5.03818M
Non operating income net other - - - - -
Operating income -45.48873M -30.40331M -20.14607M -7.77008M -14.59416M
Other operating expenses 43.62M 30.40M 20.15M 7.77M 14.59M
Interest expense 0.01M 0.00886M 0.03M 0.55M 9.67M
Tax provision -2.88385M 0.00000M 0.03M -1.22732M -0.53600M
Interest income - - - 0.18M 4.61M
Net interest income -0.01016M -0.00886M -0.03123M -0.55500M -0.33916M
Extraordinary items - - - - -0.50000M
Non recurring 1.87M - - - -
Other items - - - - -
Income tax expense -2.88385M 0.00886M 0.03M -1.22732M -0.53600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 43.62M 30.40M 20.15M 7.77M 14.59M
Cost of revenue - - - - -
Total other income expense net 0.40M -2.31886M -0.17728M -0.17594M 4.61M
Discontinued operations - - - - -
Net income from continuing ops -42.20005M -32.72217M -20.35394M -6.71870M -9.44929M
Net income applicable to common shares -45.33755M -32.72217M -20.35922M -12.16165M -17.90115M
Preferred stock and other adjustments 3.14M - 0.00529M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 60.24M 103.55M 48.65M 20.43M 8.19M
Intangible assets 3.19M 3.19M 3.19M 3.19M 3.19M
Earning assets - - - - -
Other current assets 5.31M 6.10M 1.91M 0.47M 0.14M
Total liab 10.39M 10.56M 8.12M 4.25M 6.21M
Total stockholder equity 49.86M 93.00M 40.52M 16.18M 1.98M
Deferred long term liab 0.41M - 3.19M 3.19M 3.19M
Other current liab 5.17M 2.99M 0.66M 0.49M 0.66M
Common stock 0.00762M 0.00762M 0.00320M 0.00038M 0.00166M
Capital stock 1.70M 1.71M 1.72M 1.72M 1.79M
Retained earnings -175.70134M -133.50129M -104.10546M -83.18563M -76.46393M
Other liab 2.50M 2.30M 2.99M 2.45M 3.36M
Good will 0.00000M 1.87M 1.87M 1.87M 1.87M
Other assets 0.43M 0.58M 4.03M 3.32M 3.32M
Cash 51.19M 91.35M 40.73M 13.92M 2.83M
Cash and equivalents - - - - -
Total current liabilities 7.89M 8.21M 4.66M 1.25M 2.85M
Current deferred revenue - 2.51M - - -
Net debt -51.13547M -91.03198M -39.97467M -13.11552M -1.39243M
Short term debt 0.05M 0.27M 0.28M 0.27M 1.44M
Short long term debt - - - - 1.44M
Short long term debt total 0.05M 0.32M 0.75M 0.81M 1.44M
Other stockholder equity 223.94M 224.79M 142.91M 97.65M 76.65M
Property plant equipment 0.08M 0.46M 0.66M 0.86M 0.03M
Total current assets 56.50M 97.45M 42.63M 14.39M 2.97M
Long term investments - - - - -
Net tangible assets 44.97M 86.23M 36.94M 12.60M -1.68199M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - 0.18M - -
Inventory - - - - -
Accounts payable 2.67M 2.45M 3.72M 0.49M 0.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.09017M - - - -
Additional paid in capital - - - - -
Common stock total equity 0.00762M - 0.00320M 0.00038M 0.00166M
Preferred stock total equity 1.70M - 1.71M - -
Retained earnings total equity -175.70134M - -104.10546M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.43M 0.58M 0.29M 0.13M 0.13M
Deferred long term asset charges - - - - -
Non current assets total 3.75M 6.10M 6.01M 6.04M 5.22M
Capital lease obligations 0.05M 0.32M 0.58M 0.81M -
Long term debt total - - 0.18M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01407M -0.13040M -0.08579M -0.05147M 0.00090M
Change to liabilities 2.25M -1.06785M 3.04M -0.42436M -0.89770M
Total cashflows from investing activities -0.01407M -0.13040M -0.08579M -0.05147M 0.00090M
Net borrowings - -0.17658M 0.18M -1.11940M 1.33M
Total cash from financing activities -5.13750M 81.98M 43.05M 18.71M 12.52M
Change to operating activities 0.91M -4.49935M -1.41043M -0.33025M -0.07279M
Net income -42.20005M -32.72217M -20.35394M -6.71870M -9.44929M
Change in cash -40.15988M 50.62M 26.80M 11.09M -3.12159M
Begin period cash flow 91.35M 40.73M 13.92M 2.83M 5.95M
End period cash flow 51.19M 91.35M 40.73M 13.92M 2.83M
Total cash from operating activities -34.96117M -31.22448M -16.16520M -7.56506M -15.64603M
Issuance of capital stock 17.86M 82.15M 42.87M 17.74M 12.05M
Depreciation 0.08M 0.09M 0.03M 0.03M 0.02M
Other cashflows from investing activities 0.00227M - 0.00219M - 0.00090M
Dividends paid 0.00500M 0.01M 0.01000M 0.15M 4.68M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -21.00000M 0.18M 42.88M 0.15M 4.68M
Other cashflows from financing activities -1.99500M -0.16559M 0.20M 13.39M 11.56M
Change to netincome 4.01M 6.98M 2.53M -0.60510M -5.24504M
Capital expenditures 0.02M 0.13M 0.09M 0.05M 0.05M
Change receivables - - - - -
Cash flows other operating 0.91M - -1.41043M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -40.11274M - 26.80M - -
Change in working capital 3.15M -5.56720M 1.63M -0.75460M -0.97048M
Stock based compensation 2.55M 4.67M 2.38M 0.07M 0.23M
Other non cash items 1.46M 2.31M 0.14M 0.16M -4.94355M
Free cash flow -34.97751M -31.35489M -16.25318M -7.61653M -15.64603M

Fundamentals

  • Previous Close 1.32
  • Market Cap15.40M
  • Volume16708
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-47.73883M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-12.42

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
HEPA
Hepion Pharmaceuticals Inc		 0.03 1.92% 1.35 - - - 1.06 0.04
NVO
Novo Nordisk A/S		 -1.14 0.90% 125.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.7 2.92% 123.10 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.815 0.45% 398.94 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.55 0.61% 89.55 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Hepion Pharmaceuticals Inc

399 Thornall Street, Edison, NJ, United States, 08837

Key Executives

Name Title Year Born
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. Pres, CEO & Director 1958
Mr. John T. Cavan Chief Financial Officer 1958
Dr. Todd M. Hobbs M.D. Chief Medical Officer 1969
Dr. Launa J. Aspeslet Ph.D. Chief Operating Officer NA
Dr. Daren Ure Ph.D. Chief Scientific Officer NA
Sharen Pyatetskaya Director of Investor Relations NA
Dr. Daniel J. Trepanier Ph.D. Sr. VP of Drug Devel. NA
Dr. Patrick R. Mayo Ph.D. Sr. VP of Clinical Pharmacology NA
Dr. John Z. Sullivan-Bolyai Part-Time Consultant 1948
Dr. Stephen A. Harrison M.D. Member of Scientific Advisory Board & Consultant Medical Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).